Helen Harrington’s journey: Patience, passion, and problem-solving
From developing treatments for Ebola to mastering karate with her daughters, Dr. Helen Harrington’s journey is one of resilience and curiosity.
Antibody-drug conjugates
Alentis raises $181 million to advance ADCs to the clinic
The Series D financing will support the clinical development of two ADCs.
Synaffix and BigHat Biosciences collaborate to develop AI-designed ADC
BigHat will have access to the clinical-stage ADC platform technology designed by Lonza’s Synaffix.
Abzena’s advanced drug development showcased at CPHI Milan
At CPHI Milan 2024, Abzena showcased its latest innovations in cell line development and ADC manufacturing, featuring the advanced AbZelectPRO platform and ThioBridge linker technology.
The FDA has approved Pfizer’s RSV vaccine Abrysvo for adults aged 18 to 59
The US pharma giant Pfizer recently announced that its respiratory syncytial virus (RSV) vaccine Abrysvo has received FDA approval in adults aged 18 to 59 who are at an increased risk of developing lower respiratory tract disease caused by RSV (RSV-LRTD).
Adcentrx gets FDA clearance for phase 1 trial of ADC for tumors
The FDA has given clearance to Adcentrx Therapeutics’ IND application for an antibody-drug conjugate (ADC) targeting solid tumors.
Innovations in mass spectrometry accelerate the shift toward precision medicine
Thermo Fisher’s John Lesica discusses how mass spectrometry technology enables scientific breakthroughs in genomics and proteomics to provide valuable insights for drug discovery and development.
Cellevate bags €3.2 million to smash viral vector manufacturing bottleneck
The Swedish biotech company Cellevate has raised €3.2 million in a seed round to fuel the commercialization of its nanofiber-based viral vector manufacturing technology in November.
Eli Lilly's eczema drug receives FDA approval one year after its initial rejection
The original concerns of the US regulatory agency over the manufacturing of Eli Lilly’s Ebglyss seem to have been resolved, as the FDA greenlit the antibody drug on Friday.
Adcendo and Multitude target cancer resistance to ADCs in $1BN deal
As antibody-drug conjugates (ADCs) continue to heat up in the industry, Adcendo of Denmark has gained the global rights from Multitude Therapeutics to develop the Chinese company’s ADC for the treatment of cancer outside of the Greater China region.
Innovative nanoparticle method could completely change therapeutics
In a significant leap forward for therapeutic science, researchers at Cornell University have developed a pioneering method to 'cloak' proteins, enabling their efficient delivery into living cells.
Bavarian Nordic readies 2 million vaccine doses to fight mpox outbreak
The Danish company Bavarian Nordic plans to supply up to 2 million vaccine doses this year in response to the World Health Organization’s declaration of mpox as a Public Health Emergency of International Concern (PHEIC) earlier this month.
Incyte and Syndax's immunotherapy for transplant complications receives FDA approval
The US FDA has granted approval to Niktimvo for the treatment of chronic graft-versus-host disease, a serious immune condition affecting the recipients of stem cell transplants.
FDA lifts hold on BioNTech and MediLink's ADC trial After safety revisions
Two months after placing a partial hold on a phase 1 clinical trial evaluating an antibody-drug conjugate (ADC) in cancer patients, the FDA is allowing the study to proceed with the lower doses of the treatment.
Acelyrin shifts from lead candidate despite positive phase 3 results
Acelyrin will shift away from lead candidate and cut its workforce, despite izokibep’s encouraging phase 3 results in psoriatic arthritis and hidradenitis suppurativa
First patient dosed with ADC therapy designed to disrupt tumor blood supply
Angiex has announced the beginning of the first-in-human trial of AGX101, an antibody-drug conjugate (ADC) treatment that targets solid tumors with a unique mode of action.
Jade Biosciences raises $80M to develop targeted therapies for autoimmune diseases
The fundraising will support the development of best-in-class biologics for indications across inflammation and immunology with high unmet needs.
Novartis enlists Dren Bio to co-develop bispecific antibodies for $3 billion
Eager to tap into a high-growth market, Novartis has sealed a pact worth up to $3 billion with Dren Bio to co-develop antibody treatments for cancer.
BeiGene new flagship biologics manufacturing facility opens after $800M investment
BeiGene, a global oncology company, has announced the opening of its flagship US facility, which will expand the company’s biologics manufacturing capabilities and clinical research and development activities.
Explore how Lonza's experts tackle parenteral drug and bioconjugate development challenges
In the rapidly evolving field of pharmaceuticals, the development of parenteral drugs and bioconjugates presents unique challenges and opportunities.
Funding boost to scale production for human vaccines and expand R&D labs
Botanical Solution Inc. (BSI) has successfully extended its Series A funding to over $23 million, following an additional $7.6 million investment.
CordenPharma invests €900M in expanding peptide platform to meet GLP-1 drug demand
CordenPharma, a US-based contract development and manufacturing organization (CDMO), will be making a €900 million investment over the next three years into expanding its peptide technology platform at its US and Europe sites.
SciRhom raises €63M in series A to develop antibodies against autoimmune diseases
The fundraising will support the development of SciRhom’s lead development program toward a proof-of-concept clinical trial.
HilleVax halts development of world’s most advanced norovirus vaccine after phase 2 failure
Results from the NEST-IN1 trial have shown that HilleVax’s vaccine candidate was ineffective at preventing norovirus infections in infants.
Myricx Bio using £90M series A round taking ADC pipelines through clinical proof of concept
As the industry continues its fascination with antibody-drug conjugates (ADCs), UK startup Myricx Bio heralds European biotech’s biggest Series A round this year.
EvolutionaryScale raises $142M and launches AI model for protein discovery
The new generative AI model released by EvolutionaryScale will be used by researchers and pharma companies to empower drug discovery.
Novo Nordisk's Mim8 significantly reduces bleeds in hemophilia A - plans approval submission
Once monthly treatment with Novo Nordisk’s antibody treatment reduced annual treated bleeds to zero in 95% previously untreated people with hemophilia A.
Inbar Friedrich Ben-Nun on curiosity, resiliency, and the discovery of what's next.
Director of cell and gene therapy R&D at Lonza, this week's inspiring female is Inbar who we spoke to about her passion for discovering the future and mentor support sparked her early interest in biology and informed her journey of resiliency.
Oligonucleotides in the spotlight as GSK snaps up RNA startup for up to $50 million
GSK has acquired its San Diego-based collaborator Elsie Biotechnologies to strengthen its efforts in developing oligonucleotide therapeutics.
Three Indian CDMOs ready to seize the BIOSECURE Act opportunity
In the wake of escalating tensions between the United States and China, the Biden Administration is intensifying its strategic focus on biosecurity.
BIO International 2024 to focus on partnerships amid new BIOSECURE bill
As the BIO International 2024 trade show approaches, industry insiders anticipate a significant focus on partnership discussions, driven by the pressing financial needs of biotech companies rather than the new BIOSECURE act.
Orla Cussen tells all women in science to seek out role models and let nothing stop you
Orla Cussen is associate director- engagement delivery lead, Cork, Life Sciences Manufacturing at Cognizant.
Worldwide Clinical Trials' Peter Benton on the outlook for biopharma funding
Peter Benton is president and CEO of Worldwide Clinical Trials, a full-service global CRO. We spoke with him about his insights into recent trends and factors influencing biopharma investment decisions.
Tolerizing vaccines for autoimmune diseases tempt BMS into $1.8bn collaboration
Bristol Myers Squibb partners with Repertoire Immune Medicines to develop innovative vaccines aimed at treating autoimmune disorders more selectively and effectively
SynOx takes rare tumour treatment to phase 3 with $75m Series B
Could SynOx's $75M Phase 3 Trial Be the Next Big Leap in TGCT Treatment?
CPHI North America 2024
Piramal Pharma unveils expanded services and growth vision
What is ADC specialist Piramal Pharma planning for the upcoming CPHI North America conference? We sat down with chief commercial officer Stuart Needleman to find out what's on the company's agenda.
DCAT 2024
Selkirk Pharma says success hinges on ability to deliver on manufacturing promises
In the fast-paced domain of pharmaceutical contract development and manufacturing organizations (CDMOs), Selkirk Pharma believes it stands out as a beacon of innovation and reliability.
Recent pharma industry appointments that should be on your radar - KBI Biopharma, Veranova and more
Bio Pharma Reporter and Outsourcing Pharma is back with our latest instalment of movers and shakers - breaking down all the key pharma industry appointments that you should know about. KBI Biopharma, Veranova and Kindeva Drug Delivery are among the...
AACR Annual Meeting 2024: The key announcements you need to read
Last week (April 5), the American Association for Cancer Research (AACR) welcomed the industry to the San Diego Convention Center for the AACR Annual Meeting 2024.
Ipsen licenses ‘cutting-edge’ ADC from Sutro Biopharma in $900m deal
Ipsen is expanding its oncology pipeline by securing the global licensing rights to an antibody-drug conjugate (ADC) for solid tumors from Sutro Biopharma, its first drug in the category.
Reuters Pharma USA 2024
GSK’s Maya Martinez Davis: ‘Trust is the most powerful thing in an organization’
“When you have people who like what they do and believe they’re having an impact, you can do anything – more than any project or investment. Prioritise your teams and people because they’re your biggest asset.”
Reuters Pharma USA 2024: What are key pharma players hoping to achieve?
This week, the pharma industry will descend on Pennsylvania Convention Center for Reuters Pharma USA, North America’s largest cross-functional pharma gathering.
Investors pile onto ADCs in Tubulis’ €128 million Series B2
A huge €128 million Series B2 round by German startup Tubulis indicates that the field of antibody-drug conjugates (ADCs) in oncology continues to capture investor imaginations.
Webinar: Innovations in drug delivery - tune in and join our excellent panel
As the landscape of healthcare continues to evolve, so too does the field of drug delivery.
WuXi AppTec triples peptide manufacturing capacity with new API site
WuXi AppTec has commissioned two new peptide manufacturing plants, one at its Changzhou facility and another at the new Taixing site in China.
The top 5 ADC startups favoured by venture capital investors
Antibody-drug conjugates (ADC) are booming in the biotech industry this year with mounting investment and M&A deals. Here are five ADC players that have caught the eye of investors in the last 12 months.
Hired and retired: New appointments in the pharma industry
BioPharma Reporter and Outsourcing Pharma presents its latest round-up of the movers, shakers and key announcements in the pharma industry. From Stand Up To Cancer, Astraveus and KBI Biopharma, we break down the key changes.
Women in Science: An instant passion for science and thriving in a male-dominated industry
Lisa Sellers is the CEO of Vector Laboratories, and she is passionate about staying ahead of the pharma trends.
AbbVie buys ImmunoGen for $10.1 billion, expanding cancer drug portfolio
AbbVie is acquiring rival biotech firm ImmunoGen for $10.1 billion, giving it access to ImmunoGen's flagship ovarian cancer treatment Elahere, which was granted accelerated approval from the FDA last year.
Janssen commits as first tenant in Fujifilm Diosynth US facility
Johnson & Johnson’s Janssen Supply Group is to be the first tenant in Fujifilm Diosynth Biotechnologies’ $2 billion cell culture manufacturing facility, which is planned to open in Holly Springs, North Carolina, in 2025.